• Thu, August 8, 2024

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $7 on, Aug 8th, 2024

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $10 to $7 on, Aug 8th, 2024.

Raghuram has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



This is the rating of the analyst that currently disagrees with Raghuram


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy and Held Target at $7 on, Thursday, June 27th, 2024

Like: 👍